HLA-G+ MSC Isolation for Transplant Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive drugs used for autoimmune diseases and transplantation have limitations due to toxicity, side effects, and complex dosing schedules, necessitating the development of new immunomodulatory agents with improved immunosuppressant activity, bioavailability, and extended half-life.
Innovation Solution
The isolation and use of human mesenchymal stem cells expressing HLA-G and/or HLA-E, which can be used as immunomodulatory agents to inhibit killer cell activity and prevent graft rejection, either naturally enriched or genetically modified to overexpress HLA-G, facilitating immune system regulation and transplantation therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive drugs are used to prevent graft rejection and treat autoimmune diseases, then transplantation success and immune suppression are improved, but toxicity and side effects increase
Solution Approach 1:
The patent uses HLA-G and HLA-E molecules as intermediary substances that mediate immune tolerance. These molecules are expressed on the surface of transplanted cells or administered as soluble forms to interact with immune cells (NK cells, T cells, macrophages) through specific receptors (KIR, LILRB), thereby suppressing rejection responses without the systemic toxicity of conventional immunosuppressive drugs
Solution Approach 2:
The patent employs the recipient's own immune system to recognize and tolerate the transplanted cells through HLA-G/HLA-E expression. The transplanted cells self-regulate the immune response by expressing these protective HLA molecules, which actively induce immune tolerance in the recipient without requiring external immunosuppressive medication
2Reliability
If conventional immunosuppressive drugs are used, then graft rejection is suppressed, but malignancy risk and long-term side effects increase
Solution Approach 1:
HLA-G and HLA-E molecules serve as specific mediators that selectively induce immune tolerance through interaction with inhibitory receptors on immune cells. This targeted mechanism suppresses graft rejection while avoiding the broad immunosuppression and associated malignancy risks of conventional drugs
Solution Approach 2:
The patent changes the immunological parameters by introducing HLA-G/HLA-E expression on transplanted cells, which fundamentally alters the immune recognition profile. This creates a new parameter (HLA-G/HLA-E positivity) that confers resistance to immune attack without requiring pharmacological immunosuppression
3Reliability
If HLA-G+ and HLA-E+ mesenchymal stem cells are used for transplantation, then immune system regulation is improved, but cell isolation and identification complexity increases
Solution Approach 1:
The patent uses flow cytometry with fluorescently labeled antibodies to detect and sort HLA-G+ and HLA-E+ cells. The fluorescent markers act as visual indicators that allow automated identification and separation of the desired cell population based on their HLA expression profile
Solution Approach 2:
The patent replaces manual cell isolation methods with automated flow cytometry-based sorting. This mechanical/automated system uses fluid dynamics and electrical charging to separate cells based on their HLA-G/HLA-E expression, reducing manual complexity while improving precision
Data Source
AI summary
Methods and compositions are provided for the identification and isolation of mammalian HLA-G+ MSC, HLA-E+ MSC, or HLA-G+/HLA-E+ MSC. The methods of the invention provide a means to obtain enriched HLA-G+ MSC, HLA-E+ MSC, or HLA-G+/HLA-E+ MSC populations.